BIFIDOBACTERIUM LACTIS HN019™

Learn more about our premium strain for digestive health
doctor-resp
Clinical Trials
Dose-response effect on gut transit time

AIM OF THE STUDY

This study was designed to determine the dose response effect of B. lactis HN019™ formulation on the reduction of colonic transit time in healthy adults.

PRODUCT FORMULA

  •  B.lactis HN019™  low dose (1.88 Billion CFU/day)
  •  B. lactis HN019™ (17 Billion CFU/day)

 

STUDY DESIGN

14 day, Triple blind, randomised, placebo controled

SUBJECTS

100 healthy adult patients

PUBLICATION

Scand J Gastroenterol, 25 April 2011

home-office-07-1
Clinical Trial Summary

An average reduction of colonic transit time:

  • 28 hours at 17 Billion dose (p<0.05)
  • 19 hours at 1.8 Billion dose (p<0.05)

 

For both groups, a significant reduction in  the severity of both upper and lower GI symptoms such as:

  • Constipation (p<0.01)
  • Abdominal pain (p<0.01)
  • Irregular bowel movement (p<0.05)

 

In addition to Waller study, Dietary supplementation with B. Lactis HN019 in combination with other probiotics or prebiotics improved intestinal transit time.

(Magro et al, 2014), (Ibarra et al, 2018), (Waitzburg et al, 2013)

home-office-07-1
hn019 c2
Significant Upper GI symptom reduction compared to placebo

Mean absolute change in GI symptom frequency score over the 14-day supplementation period. Self rated score on a numeric scale anchored at 1 = never and 100 = always. * p<0.05, ** p < 0.01, ***p < 0.001

Ref: Waller  et al; Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults; Scand J Gastroenterol, 25 April 2011)

011)

Significant Upper GI symptom reduction compared to placebo

Mean absolute change in GI symptom frequency score over the 14-day supplementation period. Self rated score on a numeric scale anchored at 1 = never and 100 = always. * p<0.05, ** p < 0.01, ***p < 0.001

hn019c3
Ref: Waller  et al; Dose-response effect of Bifidobacterium lactis HN019 on whole guttransit time and functional gastrointestinal symptoms in adults; Scand J Gastroenterol, 25 April 2011)
*Based on an IQVIA ProVoice® survey of Primary Care Physicians who preferred a probiotic strain for improving overall digestive health after review of select clinical studies; December 2019. This claim cannot be used without a trade mark licensing agreement from DuPont or its affiliates.
Digestive Health Products
Good gut health is key to overall health, especially when it comes to digestion. That’s why DuPont offers clinically-documented strains and pre-formulated blends to help restore our guts to optimal function and efficiency.
csp
Download White Paper

Industry Segment*:

BakeryBarsBeverageConfectioneryCulinaryDairyDietary SupplementsFrozen DessertsFruits ApplicationsPediatric NutritionPet FoodPharmaceuticals

Yes, I would like to receive email communication from DuPont Nutrition & Biosciences. I agree to the Privacy Policy and to DuPont Nutrition & Biosciences getting in contact with me.

Typically, DuPont answers within three working days; queries requiring extensive research may take longer and will be answered as soon as possible.

DuPont cares about your privacy. Your personal information (name, email, phone number and other contact data) will be stored in systems primarily hosted in the United States. This information will be used by DuPont, its affiliates, partners, and selected service providers in other countries to provide you with the product or service information requested. DuPont does not sell your personal information to third parties. To learn more, please visit our Privacy Statement at www.privacy.dupont.com

The system checks that you are in Mainland China. Do you want to switch to the Chinese version?
No
Yes